Zhongyuan Xiehe announced that the initial non-public fund-raising project “National Stem Cell Engineering Industrialization Base Phase III Construction Project” had a budget of 300 million yuan, with a total investment of 1,018,000 yuan, with a progress of 0.34%. Construction could not be started because the preliminary approval procedures were not completed. The tumor marker diagnostic reagent development project has a budget of 60 million yuan, with a total investment of 53 million yuan. The company has achieved results in a number of R&D projects, such as the approval of a Class III medical device registration certificate in February 2026. The independent financial adviser believes that from many perspectives, there has been no major change in the viability of the Phase III construction project, and it is expected that it will not be ready for use in October 2026, and the company has already carried out verification.

Zhongyuan Xiehe announced that the initial non-public fund-raising project “National Stem Cell Engineering Industrialization Base Phase III Construction Project” had a budget of 300 million yuan, with a total investment of 1,018,000 yuan, with a progress of 0.34%. Construction could not be started because the preliminary approval procedures were not completed. The tumor marker diagnostic reagent development project has a budget of 60 million yuan, with a total investment of 53 million yuan. The company has achieved results in a number of R&D projects, such as the approval of a Class III medical device registration certificate in February 2026. The independent financial adviser believes that from many perspectives, there has been no major change in the viability of the Phase III construction project, and it is expected that it will not be ready for use in October 2026, and the company has already carried out verification.